Myonex ApS: Financial statements 2025
CVR: 39905094
Source: annual report 2025, Danish Business Authority
01/01/2025 – 31/12/2025
Myonex ApS (CVR 39905094) has filed annual accounts for 2025. In 2025, the company reported a gross profit of EUR 1,009,020 and a net result of EUR 580,466 compared with EUR 2,155,499 the year before. That is a decrease of 61.1% compared with the year before. Equity in the 2025 report amounted to EUR 19,516,469. The solvency ratio was 96.9%.
- Gross Profit
- EUR 1,009,020
- Profit/Loss
- EUR 580,466
- Equity
- EUR 19,516,469
- Total Assets
- EUR 20,145,280
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2025 | - | 1M EUR | 580K EUR | 19.5M EUR | - |
| 2024 | - | 2.6M EUR | 2.2M EUR | 18.9M EUR | - |
| 2023 | - | 2.7M EUR | 1.9M EUR | 16.8M EUR | - |
| 2022 | - | 11.4M EUR | 8.8M EUR | 14.9M EUR | - |
| 2021 | - | 8.1B EUR | 6.2B EUR | 6.1B EUR | - |
Official annual report
How creditworthy is Myonex ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2025
Myonex ApS has published its annual report for 2024. Gross profit came to DKK 2,591,932, and the net result was DKK 2,155,499.
About Myonex ApS
Myonex ApS is a Danish company of the type Anpartsselskab based in København Ø, founded in 2018. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The company was previously named Myoderm ApS. The management consists of Gregory Thomas Lavin and Michael Allen Cohen. The company is owned by Myonex, LLC. In 2025, the company reported a gross profit of EUR 1,009,020 and a net result of EUR 580,466 compared with EUR 2,155,499 the year before. Equity in the 2025 report amounted to EUR 19,516,469.